FXFang Xie

Fang Xie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fang Xie has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Targeting Diagnosis of High‐Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAFV600E Mutation

    by Fang Xie, Lin Yan, Yi‐Ming Li, Yu Lan, Jing Xiao, Ming‐Bo Zhang, Zhuang Jin, Ying Zhang, Xiao‐Qi Tian, Ya‐Qiong Zhu, et al.

    Objective High-risk papillary thyroid carcinoma (PTC) patients with BRAF mutation have lymph node and distant metastasis and poor prognosis. Therefore, this study aims to develop a targeted ultrasound contrast agent for the BRAF(V600E) mutation to screen high-risk PTC at early stage. Methods The targeted lipid nanobubbles carrying BRAF(V600E) antibody were prepared using thin film hydration-sonication and avidin-biotin binding methods. The physicochemical properties and stability of the targeted nanobubbles were detected by transmission electron microscopy, atomic force microscopy, and confocal laser scanning microscopy. The target binding abilities of the targeted nanobubbles in the PTC cells (B-CPAP) overexpressed mutant BRAF(V600E) were evaluated by immunofluorescence staining, quantitative real-time polymerase chain reaction, western blot, and fluorescence microscopy. After PTC tumor models overexpressed mutant BRAF(V600E) were established, the enhanced images of targeted lipid nanobubbles and untargeted lipid nanobubbles on PTC tumors in nude mice were observed using contrast-enhanced ultrasound imaging. Results The targeted lipid nanobubbles revealed uniform, round morphology, and good stability with a nanoscale size. Besides, BRAF(V600E) monoclonal antibody was observed to be combined on the surface of lipid nanobubbles. Furthermore, the targeted nanobubbles had a good targeting diagnosis ability in PTC cells with BRAF(V600E) overexpression. Moreover, the targeted nanobubbles had better ultrasound enhancement and peak intensity of the time-intensity curve (P < .001) in PTC tumors with BRAF(V600E) overexpression as compared to the untargeted lipid nanobubbles. Conclusion The targeted lipid nanobubbles carrying BRAF(V600E) antibody could be regarded as a potential targeted ultrasound contrast agent for the diagnosis of high-risk PTC.


  • Open Access

    Evaluation of Liver Ischemia-Reperfusion Injury in Rabbits Using a Nanoscale Ultrasound Contrast Agent Targeting ICAM-1

    by Fang Xie, Zhi-Ping Li, Hong-Wei Wang, Xiang Fei, Zi-Yu Jiao, Wen-Bo Tang, Jie Tang, Yu-Kun Luo

    To assess the feasibility of ultrasound molecular imaging in the early diagnosis of liver ischemia-reperfusion injury (IRI) using a nanoscale contrast agent targeting anti-intracellular adhesion molecule-1 (anti-ICAM-1). The targeted nanobubbles containing anti-ICAM-1 antibody were prepared using the avidin-biotin binding method. Human hepatic sinusoidal endothelial cells (HHSECs) were cultured at the circumstances of hypoxia/reoxygenation (H/R) and low temperature. The rabbit liver IRI model (I/R group) was established using the Pringle’s maneuver. The time-intensity curve of the liver contrast ultrasonographic images was plotted and the peak intensity, time to peak, and time of duration were calculated. The size of the targeted nanobubbles were 148.15 ± 39.75 nm and the concentration was 3.6–7.4 × 109/ml, and bound well with the H/R HHSECs. Animal contrast enhanced ultrasound images showed that the peak intensity and time of duration of the targeted nanobubbles were significantly higher than that of common nanobubbles in the I/R group, and the peak intensity and time of duration of the targeted nanobubbles in the I/R group were also significantly higher than that in the SO group. The targeted nanobubbles have small particle size, stable characteristic, and good targeting ability, which can assess hepatic ischemia-reperfusion injury specifically, noninvasively, and quantitatively at the molecular level.